Background Current active case-finding (ACF) efforts for tuberculosis (TB) are limited by the costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis. However, it is not well understood which of these limitations has the greatest epidemiological relevance and might therefore warrant prioritization in test development.
Methods We developed a state-transition model of a one-time, community-based ACF intervention, with a fixed budget of one million United States dollars for screening and confirmatory testing. Assuming an adult population with four time the national prevalence of Uganda, we compared the impact of this intervention on TB diagnoses, mortality, and transmission when using a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus an improved confirmatory test. We considered the following test improvements: (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results (increasing delivery of positive results from 91% to 100%), (4) reduced costs (from $20 to $9 per confirmatory test). For those individuals not included in ACF efforts, TB outcomes under routine care were informed by recent natural history models.
Results In a simulated target population of 400,000 adults, 6,421 (1.6%; 95% uncertainty range [UR] 5,316-7,531) had TB disease, and 873 (612-1,182) were projected to die of TB in the absence of ACF. Assuming current tests, ACF efforts could reach 83,808 (59,388-118,601; 21% of the target population) people under the allotted budget, connecting 651 (429-983) individuals with TB to treatment and averting 76 (39-132) deaths. Of all hypothetical confirmatory test improvements modeled, higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 14% [4-26%]). However, considering mortality or transmission as a metric, the largest reductions resulted from tests that provided immediate turn-around of results (by 11% [5-18%]).
Conclusion Making confirmatory tests for community-based TB screening more accessible and rapid may lead to greater population health benefits than further increasing sensitivity. Nonetheless, achieving large (>20%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.
Competing Interest StatementC.M. D. reports research grants from the US NIH, German Ministry of Education and Research, German Alliance for Global Health research, USAID, FIND, German Center for Infection Research, UNAIDS, World Health Organization (WHO). C. M. D. also reports a role as academic editor for PLoS Med and on technical advisory group Tuberculosis diagnostics for WHO. A. C. reports grants to institution from U.S. NIH, Global Health Labs, Stop TB Partnership, and Bill and Melinda Gates Foundation and unpaid participation on an Advisory Board for EDCTP-funded TB diagnostic trial. G. T. reports grants from the EDCTP2 program supported by the EU (RIA2018D-2509, PreFIT; RIA2018D-2493, SeroSelectTB; RIA2020I-3305, CAGE-TB) and the National Institutes of Health (D43TW010350; U01AI152087; U54EB027049; R01AI136894). F.M.M. reports a research grant from the Bill and Melinda Gates Foundation. All other authors report no potential conflicts.
Funding StatementThis work was supported by the German Center for Infection Research (DZIF) (grant number 80295MD001 and grant number 8029802812) and by the National Institute of Allergy and Infectious Diseases (grant number U01AI152087) and the National Heart Lung and Blood Institute (grant numbers R01HL138728 and R01HL153611) of the U.S. National Institutes of Health (NIH).
Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data AvailabilityAll data produced in the present work are contained in the manuscript
Comments (0)